Clinical Trials Browser

Phase 1/2 × Terminated × Papillomavirus Infections × Clear all

NCT03610581 2025-02-04

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Phase 1/2 Terminated

9 enrolled 13 charts

Papillomavirus Infections